Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome
NCT01983722 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2026-01-23
Summary
Expanded access to Stiripentol for patients with Dravet Syndrome.
Conditions
Interventions
- DRUG
-
Stiripentol
Sponsors & Collaborators
-
Children's Hospital Medical Center, Cincinnati
lead OTHER
Eligibility
- Min Age
- 6 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Treatment Development of Triheptanoin (G1D)
NCT03041363 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Pathogenesis of Rett Syndrome
NCT00004807 ·Status: COMPLETED ·Phase: NA
-
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
NCT03813238 ·Status: COMPLETED ·Phase: PHASE3
-
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
NCT02318563 ·Status: WITHDRAWN ·Phase: PHASE3
-
Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity
NCT00607542 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pathogenesis of Adverse Drug Reactions
NCT00224952 ·Status: COMPLETED
-
A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
NCT02682927 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
NCT04200352 ·Status: TERMINATED ·Phase: PHASE3
-
Intrathecal Baclofen and Pediatric Dystonia
NCT06606574 ·Status: RECRUITING ·Phase: NA
-
Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1
NCT01586052 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
NCT03848832 ·Status: TERMINATED ·Phase: PHASE3
-
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
NCT04988867 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
NCT04442295 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
NCT02091206 ·Status: COMPLETED ·Phase: PHASE2
-
Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects
NCT00122044 ·Status: COMPLETED ·Phase: PHASE2
-
Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
NCT03301532 ·Status: COMPLETED ·Phase: PHASE2
-
Ceftaroline Diffusion Into Cerebrospinal Fluid of Children
NCT02600793 ·Status: UNKNOWN ·Phase: PHASE1
-
GABA Biomarkers in Dravet Syndrome
NCT05651204 ·Status: RECRUITING
-
A Novel Approach to Infantile Spasms
NCT03347526 ·Status: SUSPENDED ·Phase: PHASE3
-
Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population
NCT00207935 ·Status: COMPLETED ·Phase: PHASE4
-
Placebo Controlled Trial of Dextromethorphan in Rett Syndrome
NCT01520363 ·Status: COMPLETED ·Phase: PHASE2
-
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
NCT03181399 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome.
NCT03059160 ·Status: UNKNOWN ·Phase: PHASE2
-
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
NCT02224703 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
NCT02036853 ·Status: COMPLETED ·Phase: PHASE2